[Benoxaprofene: pharmacokinetic profile in the normal subject and patients with renal insufficiency; evaluation of anticipated serum levels].
The pharmacokinetic profile of benoxaprofene, administered in a single oral dose of 600 mg, has been determined comparatively in 5 normal subjects and 15 patients with renal insufficiency (five of whom were on chronic hemodialysis). In the normal subject, the half-absorption time (Ka) was 0.63 hours; a mean theoretical maximal concentration of 47.3 micrograms/ml was reached 3.6 hours after administration of the drug. The decrease in serum levels was particularly slow, the coefficient of total elimination (Ke) being 0.0241(h-1) and the biological half-life attaining 28.8 hours. :The total clearance (Ct = 4.8 ml/min/1.73 m2) and renal clearance (Cr =1.6 ml/min/1.73 m2) values were low. 13.9% of the ingested dose of benoxaprofene was recovered in the 24 hours urinary volume. Renal insufficiency does not significantly change the pharmacokinetic parameters. It appears advisable to reduce the dosage by half only in patients with a Cr clearance of less than 10-20 ml/min/1.73 m2. The theoretical serum values reached after administration of 600 mg benoxaprofene repeated every 6-12-24-36 or 48 hours have been calculated and it has been found that effective concentrations can be obtained by administration of 600 mg every 12 or 24 hours.
D000284:Administration, Oral; D000328:Adult; D001583:Benzoxazoles / Q000097:blood / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006207:Half-Life; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000097:blood / Q000627:therapeutic use*; D006435:Renal Dialysis
D001583:Benzoxazoles; D011422:Propionates; C011677:benoxaprofen
Benoxaprofène: profil pharmacocinétique chez le sujet normal et l'insuffisant rènal, évaluation prévisionnelle des taux sériques.